Effect of vasoconstrictor coupling factor 6 on gene expression profile in human vascular endothelial cells: Enhanced release of asymmetric dimethylarginine

Journal of Hypertension

Volumn 24, Issue 3, 2006, Pages 489-497

  Tanaka, Makoto ^a   Osanai, Tomohiro ^a   Murakami, Reiichi ^a   Sasaki, Satoko ^a   Tomita, Hirofumi ^a   Maeda, Naotaka ^a   Satoh, Kei ^b   Magota, Koji ^c   Okumura, Ken ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b Institute of Brain Science

^c DAIICHI SANKYO CO   (Japan)

Author keywords

ATP synthase; Coupling factor 6; Endothelium; Hypertension; Nitric oxide; Nitric oxide synthase; Prostaglandins

Indexed keywords

COUPLING FACTOR 6; DIMETHYLARGININASE; DIMETHYLARGININASE 2; ESTROGEN RECEPTOR BETA; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; N(G),N(G) DIMETHYLARGININE; NEU DIFFERENTIATION FACTOR; NITRIC OXIDE SYNTHASE INHIBITOR; PROTEIN ARGININE METHYLTRANSFERASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; RELAXIN; RELAXIN 1; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VASOCONSTRICTOR AGENT;

ARTICLE; CELL INFILTRATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DNA MICROARRAY; DRUG EXPOSURE; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME SYNTHESIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN FOLDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

EID: 32944475009     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000209985.66853.1e     Document Type: Article

References (31)

1. Knowles AF, Guillory RJ, Racker E. Partial resolution of the enzymes catalyzing oxidative phosphorylation: XXIV. A factor required for the binding of mitochondrial adenosine triphosphatase to the inner mitochondrial membrane. J Biol Chem 1971; 246:2672-2679.
2. 2 in the spontaneously hypertensive rat. Prostaglandins 1985; 29:621-628.
3. 2 in spontaneously hypertensive rats during maturation and concomitant development of hypertension. Jpn Circ J 1990; 54:507-514.
4. Osanai T, Kamada T, Fujiwara N, Takeshi K, Koki T, Masao K, et al. A novel inhibitory effect on prostacyclin synthesis of coupling factor 6 extracted from the heart of spontaneously hypertensive rats. J Biol Chem 1998; 273:31778-31783.
5. Osanai T, Tanaka M, Kamada T, Nakano T, Takahashi K, Okada S, et al. Mitochondrial coupling factor 6 as a potent endogenous vasoconstrictor. J Clin Invest 2001; 108:1023-1030.
6. Osanai T, Nakamura M, Sasaki S, Tomita H, Saitoh M, Osawa H, et al. Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease. Kidney Int 2003; 64:2291-2297.
7. G-dimethylarginine by human endothelial cells. Endothelium 1993; 1:137-140.
8. Osanai T, Saitoh M, Sasaki S, Tomita H, Matsunaga T, Okumura K. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 2003; 42:985-990.
9. G-dimethylarginine dimethylaminohydrolase from rat kidney. Biochim Biophys Acta 1997; 1337:6-10.
10. G-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 1989; 264:10205-10209.
11. Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension. Modulation of nitric oxide synthesis by salt intake. Circulation 2000; 101:856-861.
12. Osanai T, Okada S, Sirato K, Nakano T, Saitoh M, Magota K, et al. Mitochondrial coupling factor 6 is present on the surface of human vascular endothelial cells and is released by shear stress. Circulation 2001; 104:3132-3136.
13. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
14. Ye L, Martin TA, Parr C, Harrison GM, Mansel RE, Jiang WG. Biphasic effects of 17-beta-estradiol on expression of occludin and transendothelial resistance and paracellular permeability in human vascular endothelial cells. J Cell Physiol 2003; 196:362-369.
15. Fuchs T, Allgayer H. Transcriptional regulation of the urokinase receptor (u-PAR): a central molecule of invasion and metastasis. Biol Chem 2003; 384:755-761.
16. Garratt AN, Ozcelik C, Birchmeier C. ErbB2 pathways in heart and neural diseases. Trends Cardiovasc Med 2003; 13:80-86.
17. Bani D. Relaxin: a pleiotropic hormone. Gen Pharmacol 1997; 28:13-22.
18. Ross ADB, Chrishan SS, Tanya CDB, Sharon L, Antonia AC, Irna GTR, et al. Human relaxin gene 3 (H3) and the equivalent mouse relaxin (M3) gene: novel members of the relaxin peptide family. J Biol Chem 2002; 277:1148-1157.
19. Hsu SY, Nakabayashi K, Nishi S, Kumagai J, Kudo M, Sherwood OD, et al. Activation of orphan receptors by the hormone relaxin. Science 2002; 295:671-674.
20. Massicotte G, Parent A, St. Louis J. Blunted responses to vasoconstrictors in mesenteric vasculature but not in portal vein of spontaneously hypertensive rates treated with relaxin. Proc Soc Exp Biol Med 1989; 190:254-259.
21. Dschietzig T, Richter C, Bartsch C, Laule M, Armbruster FP, Baumann G, et al. The pregnancy hormone relaxin is a player in human heart failure. FASEB J 2001; 15:2187-2195.
22. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87:99-105.
23. Leiper JM, Maria JS, Chubb A, MacAllister RJ, Charles IG, Whitley GSJ, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deaminases. Biochem J 1999; 343:209-214.
24. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction-dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99:3092-3095.
25. Cybulsky MI, Gimbrone MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251:788-791.
26. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine: a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98:1842-1847.
27. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95:2068-2074.
28. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boger RH, Bode-Boger SM, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33:652-658.
29. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572-575.
30. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998; 62:2425-2430.
31. Osanai T, Sasaki S, Kamada T, Fujiwara N, Nakano T, Tomita H, et al. Circulating coupling factor 6 in human hypertension: role of reactive oxygen species. J Hypertens 2003; 21:2323-2328.